Free Trial
→ One page of the SpaceX S-1 will move this stock overnight (From Behind the Markets) (Ad)tc pixel Free ABBV Stock Alerts

AbbVie (ABBV) Financials

AbbVie logo
$212.79 -2.91 (-1.35%)
As of 03:58 PM Eastern
Compare
Annual Income Statements for AbbVie

Annual Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 5,144 5,953 5,309 5,687 7,882 4,616 11,542 11,836 4,863 4,278 4,226
Consolidated Net Income / (Loss)		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286 4,233
Net Income / (Loss) Continuing Operations		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286 4,233
Total Pre-Tax Income 		6,645 7,884 7,727 5,197 8,426 3,398 12,989 13,477 6,250 3,716 6,597
Total Operating Income		 7,537 9,340 9,545 6,383 12,983 11,363 17,924 18,117 12,757 9,137 15,075
Total Gross Profit		 18,359 19,806 21,174 25,035 25,827 29,041 38,751 39,943 33,903 39,430 37,940
Total Revenue		 22,859 25,638 28,216 32,753 33,266 45,804 56,197 58,054 54,318 56,334 61,160
Operating Revenue		 22,859 25,638 28,216 32,753 33,266 45,804 56,197 58,054 54,318 56,334 61,160
Total Cost of Revenue		 4,500 5,832 7,042 7,718 7,439 16,763 17,446 18,111 20,415 16,904 23,220
Operating Cost of Revenue		 4,500 5,832 7,042 7,718 7,439 16,763 17,446 18,111 20,415 16,904 23,220
Total Operating Expenses		 10,822 10,466 11,629 18,652 12,844 17,678 20,827 21,826 21,146 30,293 22,865
Selling, General & Admin Expense		 6,387 5,881 6,295 7,399 6,942 11,299 13,473 15,260 13,650 17,509 14,010
Research & Development Expense		 4,435 4,585 5,334 10,753 6,792 6,379 6,922 6,510 7,675 12,791 9,096
Other Operating Expenses / (Income)		 - - 0.00 500 -890 0.00 432 56 -179 -7.00 -241
Total Other Income / (Expense), net		 -892 -1,456 -1,818 -1,186 -4,557 -7,965 -4,935 -4,640 -6,507 -5,421 -8,478
Interest & Investment Income		 -686 -965 -1,004 -1,144 -1,509 -2,280 -2,384 -2,044 -1,684 -2,160 -2,627
Other Income / (Expense), net		 -206 -491 -814 -42 -3,048 -5,685 -2,551 -2,596 -4,823 -3,261 -5,851
Income Tax Expense		 1,501 1,931 2,418 -490 544 -1,224 1,440 1,632 1,377 -570 2,364
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - 0.00 0.00 6.00 7.00 9.00 10 8.00 7.00
Basic Earnings per Share		 $3.15 $3.65 $3.31 $3.67 $5.30 $2.73 $6.48 $6.65 $2.73 $2.40 $2.37
Weighted Average Basic Shares Outstanding		 1.63B 1.62B 1.60B 1.54B 1.48B 1.67B 1.77B 1.77B 1.77B 1.77B 1.77B
Diluted Earnings per Share		 $3.13 $3.63 $3.30 $3.66 $5.28 $2.72 $6.45 $6.63 $2.72 $2.39 $2.36
Weighted Average Diluted Shares Outstanding		 1.64B 1.63B 1.60B 1.55B 1.48B 1.67B 1.78B 1.78B 1.77B 1.77B 1.77B
Weighted Average Basic & Diluted Shares Outstanding		 1.63B 1.63B 1.60B 1.55B 1.48B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B

Quarterly Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 1,778 822 1,369 1,370 1,561 -22 1,286 938 186 1,816 695
Consolidated Net Income / (Loss)		 1,781 824 1,372 1,373 1,564 -23 1,289 941 188 1,815 697
Net Income / (Loss) Continuing Operations		 1,781 824 1,372 1,373 1,564 -23 1,289 941 188 1,815 697
Total Pre-Tax Income 		1,953 1,212 1,755 2,146 2,084 -2,269 1,661 1,554 714 2,668 1,039
Total Operating Income		 2,281 3,195 2,798 3,998 3,831 -1,490 3,733 4,894 1,904 4,544 3,990
Total Gross Profit		 7,376 8,035 8,052 10,260 10,166 11,807 9,341 11,077 7,792 9,978 10,040
Total Revenue		 13,927 14,301 12,310 14,462 14,460 15,102 13,343 15,423 15,776 16,618 15,002
Operating Revenue		 13,927 14,301 12,310 14,462 14,460 15,102 13,343 15,423 15,776 16,618 15,002
Total Cost of Revenue		 6,551 6,266 4,258 4,202 4,294 3,295 4,002 4,346 7,984 6,640 4,962
Operating Cost of Revenue		 6,551 6,266 4,258 4,202 4,294 3,295 4,002 4,346 7,984 6,640 4,962
Total Operating Expenses		 5,095 4,840 5,254 6,262 6,335 13,297 5,608 6,183 5,888 5,434 6,050
Selling, General & Admin Expense		 3,372 2,913 3,315 4,314 4,205 6,530 3,541 4,076 3,569 3,072 3,578
Research & Development Expense		 1,723 1,927 1,939 1,948 2,130 6,774 2,067 2,131 2,319 2,579 2,472
Total Other Income / (Expense), net		 -328 -1,983 -1,043 -1,852 -1,747 -779 -2,072 -3,340 -1,190 -1,876 -2,951
Interest & Investment Income		 -398 -378 -453 -506 -591 -610 -627 -678 -667 -655 -645
Other Income / (Expense), net		 70 -1,605 -590 -1,346 -1,156 -169 -1,445 -2,662 -523 -1,221 -2,306
Income Tax Expense		 172 388 383 773 520 -2,246 372 613 526 853 342
Net Income / (Loss) Attributable to Noncontrolling Interest		 3.00 2.00 3.00 3.00 3.00 -1.00 3.00 3.00 2.00 -1.00 2.00
Basic Earnings per Share		 $1.00 $0.46 $0.77 $0.77 $0.88 ($0.02) $0.72 $0.52 $0.10 $1.03 $0.39
Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Diluted Earnings per Share		 $1.00 $0.45 $0.77 $0.77 $0.88 ($0.03) $0.72 $0.52 $0.10 $1.02 $0.39
Weighted Average Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Cash Dividends to Common per Share		 - - $1.55 $1.55 - - $1.64 $1.64 - - $1.73

Annual Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 51 -3,299 4,203 -2,014 32,635 -31,475 1,297 -545 3,613 -7,290 -295
Net Cash From Operating Activities		 7,535 7,041 9,960 13,427 13,324 17,588 22,777 24,943 22,839 18,806 19,030
Net Cash From Continuing Operating Activities		 7,535 7,041 9,960 13,427 13,324 17,588 22,777 24,943 22,839 18,806 19,030
Net Income / (Loss) Continuing Operations		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286 4,233
Consolidated Net Income / (Loss)		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286 4,233
Depreciation Expense		 417 425 425 471 464 666 803 778 752 764 762
Amortization Expense		 419 764 1,076 1,294 1,553 5,805 7,718 7,689 7,946 7,622 7,377
Non-Cash Adjustments To Reconcile Net Income		 1,051 1,360 2,515 7,052 1,663 2,961 2,157 3,895 4,216 6,594 3,017
Changes in Operating Assets and Liabilities, net		 504 -1,461 635 -1,077 1,762 3,534 550 736 5,052 -460 3,641
Net Cash From Investing Activities		 -12,936 -6,074 -274 -1,006 596 -37,557 -2,344 -623 -2,009 -20,820 -6,643
Net Cash From Continuing Investing Activities		 -12,936 -6,074 -274 -1,006 596 -37,557 -2,344 -623 -2,009 -20,820 -6,643
Purchase of Property, Plant & Equipment		 -532 -479 -529 -638 -552 -798 -787 -695 -777 -974 -1,214
Acquisitions		 -11,488 -2,495 - 0.00 0.00 -38,260 -525 -255 0.00 -17,493 -204
Purchase of Investments		 -1,815 -5,577 -2,538 -2,528 -1,718 -1,411 -1,496 -1,977 -1,300 -3,097 -5,272
Sale and/or Maturity of Investments		 899 2,359 2,793 2,160 2,699 1,525 98 1,530 55 555 76
Other Investing Activities, net		 0.00 118 0.00 0.00 167 1,387 366 774 13 189 -29
Net Cash From Financing Activities		 5,771 -3,928 -5,512 -14,396 18,708 -11,501 -19,039 -24,803 -17,222 -5,211 -12,724
Net Cash From Continuing Financing Activities		 5,771 -3,928 -5,512 -14,396 18,708 -11,501 -19,039 -24,803 -17,222 -5,211 -12,724
Repayment of Debt		 -4,018 -6,010 -25 -6,035 -4,501 -5,675 -9,390 -14,403 -4,101 -14,564 -9,527
Repurchase of Common Equity		 -7,768 -6,102 -1,410 -12,054 -1,053 -998 -934 -1,487 -2,010 -1,807 -1,003
Payment of Dividends		 -3,294 -3,717 -4,107 -5,580 -6,366 -7,716 -9,261 -10,043 -10,539 -11,025 -11,657
Issuance of Debt		 20,696 11,633 44 9,278 30,783 3,000 1,000 2,000 0.00 21,971 9,291
Other Financing Activities, net		 155 268 -14 -5.00 -155 -112 -454 -870 -572 214 172
Effect of Exchange Rate Changes		 - -338 29 -39 7.00 -5.00 -97 -62 5.00 -65 42
Cash Interest Paid		 536 986 1,099 1,215 1,794 2,619 2,712 2,546 2,469 2,811 3,002

Quarterly Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 4,528 -473 5,253 -4,937 -5,873 -1,733 -349 1,292 -838 -400 4,162
Net Cash From Operating Activities		 7,574 4,753 4,040 2,271 5,447 7,048 1,635 5,153 7,024 5,218 3,829
Net Cash From Continuing Operating Activities		 7,574 4,753 4,040 2,271 5,447 7,048 1,635 5,153 7,024 5,218 3,829
Net Income / (Loss) Continuing Operations		 1,781 824 1,372 1,373 1,564 -23 1,289 941 188 1,815 697
Consolidated Net Income / (Loss)		 1,781 824 1,372 1,373 1,564 -23 1,289 941 188 1,815 697
Depreciation Expense		 196 187 183 184 191 206 181 186 192 203 188
Amortization Expense		 2,039 1,889 1,891 1,947 1,888 1,896 1,858 1,864 1,871 1,784 1,748
Non-Cash Adjustments To Reconcile Net Income		 1,786 1,105 76 689 -25 5,854 -603 201 2,551 868 594
Changes in Operating Assets and Liabilities, net		 1,772 748 518 -1,922 1,829 -885 -1,090 1,961 2,222 548 602
Net Cash From Investing Activities		 -369 -800 -9,588 -1,102 -8,256 -1,874 -735 -1,181 -3,264 -1,463 -574
Net Cash From Continuing Investing Activities		 -369 -800 -9,588 -1,102 -8,256 -1,874 -735 -1,181 -3,264 -1,463 -574
Purchase of Property, Plant & Equipment		 -219 -205 -193 -241 -249 -291 -235 -269 -381 -329 -265
Acquisitions		 - - -9,199 - -8,294 - -204 - - - 0.00
Purchase of Investments		 -165 -587 -196 -859 -223 -1,819 -334 -952 -2,809 -1,167 -266
Other Investing Activities, net		 10 -22 -6.00 -5.00 3.00 197 38 33 -77 -1.00 -43
Net Cash From Financing Activities		 -2,661 -4,449 10,819 -6,097 -3,072 -6,861 -1,258 -2,710 -4,590 -4,166 919
Net Cash From Continuing Financing Activities		 -2,661 -4,449 10,819 -6,097 -3,072 -6,861 -1,258 -2,710 -4,590 -4,166 919
Repayment of Debt		 28 -1,796 -5,183 -3,348 -371 -5,662 -2,959 -3,756 -1,979 -777 -1,998
Repurchase of Common Equity		 -4.00 -41 -1,324 -9.00 -17 -457 -961 -12 -4.00 -26 -1,489
Payment of Dividends		 -2,627 -2,626 -2,772 -2,750 -2,751 -2,752 -2,925 -2,910 -2,911 -2,911 -3,086
Issuance of Debt		 - - 19,971 - - 2,000 5,587 3,963 241 -500 7,492
Effect of Exchange Rate Changes		 -16 23 -18 -9.00 8.00 -46 9.00 30 -8.00 11 -12

Annual Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 53,050 66,099 70,786 59,352 89,115 150,565 146,529 138,805 134,711 135,161 133,960
Total Current Assets		 16,314 16,187 21,223 16,945 49,519 24,173 27,928 28,463 33,002 25,582 29,062
Cash & Equivalents		 8,399 5,100 9,303 7,289 39,924 8,449 9,746 9,201 12,814 5,524 5,229
Accounts Receivable		 4,730 4,758 5,088 5,384 5,428 8,822 9,977 11,254 11,155 10,919 12,589
Inventories, net		 1,719 1,444 1,605 1,605 1,813 3,310 3,128 3,579 4,099 4,181 4,951
Prepaid Expenses		 1,458 3,562 4,741 1,895 2,354 3,562 4,993 4,401 4,932 4,927 6,293
Plant, Property, & Equipment, net		 2,565 2,604 2,803 2,883 2,962 5,248 5,110 4,935 4,989 5,134 5,628
Total Noncurrent Assets		 34,171 47,308 46,760 39,524 36,634 121,144 113,491 105,407 96,720 104,445 99,270
Long-Term Investments		 145 1,783 2,090 1,420 93 293 277 241 304 279 268
Goodwill		 13,168 15,416 15,785 15,663 15,604 33,124 32,379 32,156 32,293 34,956 35,640
Intangible Assets		 19,709 28,897 27,559 21,233 18,649 82,876 75,951 67,439 55,610 60,068 52,641
Other Noncurrent Operating Assets		 1,149 1,212 1,326 1,208 2,288 4,851 4,884 5,571 8,513 9,142 10,721
Total Liabilities & Shareholders' Equity		 53,050 66,099 70,786 59,352 89,115 150,565 146,529 138,805 134,711 135,161 133,960
Total Liabilities		 49,105 61,463 65,689 67,798 97,287 137,468 131,093 121,518 124,314 131,797 137,188
Total Current Liabilities		 10,894 9,781 16,641 17,239 15,585 28,661 35,194 29,538 37,841 38,749 43,289
Short-Term Debt		 2,431 402 6,415 5,308 3,753 8,502 12,495 4,136 7,191 6,804 8,555
Accounts Payable		 8,463 9,379 10,226 11,931 11,832 20,159 22,699 25,402 30,650 31,945 34,734
Total Noncurrent Liabilities		 38,211 51,682 49,048 50,559 81,702 108,807 95,899 91,980 86,473 93,048 93,899
Long-Term Debt		 32,935 44,792 46,558 49,492 62,975 77,554 64,189 59,135 52,194 60,340 58,941
Noncurrent Deferred & Payable Income Tax Liabilities		 5,276 6,890 2,490 1,067 1,130 3,646 3,009 2,190 1,952 2,579 2,389
Other Noncurrent Operating Liabilities		 - - - - 17,597 27,607 28,701 30,655 32,327 30,129 32,569
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,945 4,636 5,097 -8,446 -8,172 13,097 15,436 17,287 10,397 3,364 -3,228
Total Preferred & Common Equity		 3,945 4,636 5,097 -8,446 -8,172 13,076 15,408 17,254 10,360 3,325 -3,270
Total Common Equity		 3,945 4,636 5,097 -8,446 -8,172 13,076 15,408 17,254 10,360 3,325 -3,270
Common Stock		 13,097 13,696 14,288 14,774 15,211 17,402 18,323 19,263 20,198 21,351 22,513
Retained Earnings		 2,248 4,378 5,459 3,368 4,717 1,055 3,127 4,784 -1,000 -7,900 -15,493
Treasury Stock		 -8,839 -10,852 -11,923 -24,108 -24,504 -2,264 -3,143 -4,594 -6,533 -8,201 -9,146
Accumulated Other Comprehensive Income / (Loss)		 -2,561 -2,586 -2,727 -2,480 -3,596 -3,117 -2,899 -2,199 -2,305 -1,925 -1,144
Noncontrolling Interest		 - - - - 0.00 21 28 33 37 39 42

Quarterly Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 135,367 136,221 134,711 148,874 141,937 143,422 135,161 136,165 137,182 133,898 136,463
Total Current Assets		 28,852 33,224 33,002 38,871 33,816 27,785 25,582 27,675 29,261 28,539 33,529
Cash & Equivalents		 8,759 13,287 12,814 18,067 13,130 7,257 5,524 5,175 6,467 5,629 9,391
Accounts Receivable		 11,491 11,412 11,155 11,949 11,724 11,472 10,919 12,477 12,637 12,769 12,479
Inventories, net		 4,055 3,981 4,099 4,245 4,218 4,450 4,181 4,526 4,960 4,938 5,049
Prepaid Expenses		 4,540 4,541 4,932 4,608 4,717 4,578 4,927 5,496 5,197 5,161 6,610
Plant, Property, & Equipment, net		 4,943 4,934 4,989 4,980 5,023 5,141 5,134 5,237 5,283 5,483 5,687
Total Noncurrent Assets		 101,572 98,063 96,720 105,023 103,098 110,496 104,445 103,253 102,638 99,876 97,247
Long-Term Investments		 288 275 304 305 272 267 279 287 310 291 268
Goodwill		 32,224 32,091 32,293 33,426 33,386 35,295 34,956 35,285 35,638 35,626 35,570
Intangible Assets		 62,862 58,603 55,610 62,225 60,243 66,646 60,068 58,489 57,031 54,315 50,873
Other Noncurrent Operating Assets		 6,198 7,094 8,513 9,067 9,197 8,288 9,142 9,192 9,659 9,644 10,536
Total Liabilities & Shareholders' Equity		 135,367 136,221 134,711 148,874 141,937 143,422 135,161 136,165 137,182 133,898 136,463
Total Liabilities		 122,469 124,092 124,314 140,827 135,116 137,351 131,797 134,703 137,320 136,497 143,075
Total Current Liabilities		 32,239 34,773 37,841 41,522 41,915 43,062 38,749 36,403 39,767 39,391 42,100
Short-Term Debt		 5,203 5,115 7,191 10,196 12,586 12,570 6,804 5,362 7,522 5,772 8,326
Accounts Payable		 27,036 29,658 30,650 31,326 29,329 30,492 31,945 31,041 32,245 33,619 33,774
Total Noncurrent Liabilities		 90,230 89,319 86,473 99,305 93,201 94,289 93,048 98,300 97,553 97,106 100,975
Long-Term Debt		 55,812 55,631 52,194 63,805 58,048 58,509 60,340 64,527 62,959 62,971 64,532
Noncurrent Deferred & Payable Income Tax Liabilities		 2,124 2,044 1,952 2,722 2,726 2,749 2,579 2,582 2,554 2,480 2,332
Other Noncurrent Operating Liabilities		 32,294 31,644 32,327 32,778 32,427 33,031 30,129 31,191 32,040 31,655 34,111
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 12,898 12,129 10,397 8,047 6,821 6,071 3,364 1,462 -138 -2,599 -6,612
Total Preferred & Common Equity		 12,866 12,094 10,360 8,007 6,778 6,032 3,325 1,420 -183 -2,642 -6,656
Total Common Equity		 12,866 12,094 10,360 8,007 6,778 6,032 3,325 1,420 -183 -2,642 -6,656
Common Stock		 19,857 20,039 20,198 20,674 20,897 21,178 21,351 21,826 22,005 22,309 22,980
Retained Earnings		 1,789 933 -1,000 -2,384 -3,768 -4,964 -7,900 -9,527 -11,503 -14,234 -17,872
Treasury Stock		 -6,528 -6,525 -6,533 -7,829 -7,838 -7,848 -8,201 -9,137 -9,147 -9,143 -10,611
Accumulated Other Comprehensive Income / (Loss)		 -2,252 -2,353 -2,305 -2,454 -2,513 -2,334 -1,925 -1,742 -1,538 -1,574 -1,153
Noncontrolling Interest		 32 35 37 40 43 39 39 42 45 43 44

Annual Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 1,767,384,632.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 1,767,384,632.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 2.39
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 14.52% 12.16% 10.06% 16.08% 1.57% 37.69% 22.69% 3.30% -6.44% 3.71% 8.57%
EBITDA Growth		 130.32% 22.91% 1.93% -20.78% 47.45% 1.65% 96.67% 0.39% -30.67% -14.25% 21.74%
EBIT Growth		 165.62% 20.71% -1.33% -27.37% 56.68% -42.85% 170.75% 0.96% -48.88% -25.94% 56.98%
NOPAT Growth		 128.42% 20.87% -7.01% 6.51% 73.87% 27.27% 3.11% -0.09% -37.54% 5.95% -8.21%
Net Income Growth		 189.97% 15.73% -10.82% 7.12% 38.60% -41.36% 149.87% 2.56% -58.86% -12.05% -1.24%
EPS Growth		 184.55% 15.97% -9.09% 10.91% 44.26% -48.48% 137.13% 2.79% -58.97% -12.13% -1.26%
Operating Cash Flow Growth		 324.51% -6.56% 41.46% 34.81% -0.77% 32.00% 29.50% 9.51% -8.44% -17.66% 1.19%
Free Cash Flow Firm Growth		 -486.93% 70.65% 152.22% 718.79% 86.95% -285.00% 143.10% 10.46% -9.22% -89.63% 517.60%
Invested Capital Growth		 157.74% 35.32% 10.97% -20.17% -49.72% 387.52% -9.26% -13.32% -20.29% 14.14% -9.17%
Revenue Q/Q Growth		 4.33% 1.57% 3.46% 1.76% 1.21% 12.68% 1.86% 0.41% -1.49% 1.44% 2.54%
EBITDA Q/Q Growth		 61.15% 2.37% -7.27% -29.71% 89.65% -19.07% 30.93% -4.85% -10.41% -18.43% 38.95%
EBIT Q/Q Growth		 70.49% 1.90% -8.81% -35.56% 128.29% -43.76% 59.44% -8.28% -18.92% -35.61% 117.44%
NOPAT Q/Q Growth		 52.33% -0.86% -16.48% -23.71% 68.77% 44.38% -8.22% -0.83% -18.97% 6.90% -25.84%
Net Income Q/Q Growth		 82.61% -2.07% -20.14% -24.82% 142.15% -37.41% 53.13% -11.72% -25.27% -16.50% 76.74%
EPS Q/Q Growth		 84.12% -2.16% -19.71% 0.00% 0.00% -42.49% 58.87% -11.48% -25.89% -16.72% 80.15%
Operating Cash Flow Q/Q Growth		 27.73% -5.65% 11.70% 6.40% -0.87% 9.86% 0.98% 10.42% -10.48% 13.90% -8.77%
Free Cash Flow Firm Q/Q Growth		 18.52% -8.45% -75.09% 102.47% 104.98% -17.32% -18.28% 10.42% -7.97% 687.62% -30.53%
Invested Capital Q/Q Growth		 -2.25% -1.12% 10.09% -14.37% -47.61% -4.01% 0.29% -3.31% -4.46% -7.07% -2.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 80.31% 77.25% 75.04% 76.44% 77.64% 63.40% 68.96% 68.80% 60.98% 69.99% 62.03%
EBITDA Margin		 35.73% 39.15% 36.26% 24.75% 35.93% 26.52% 42.52% 41.32% 30.62% 25.32% 28.39%
Operating Margin		 32.97% 36.43% 33.83% 19.49% 39.03% 24.81% 31.89% 31.21% 23.49% 16.22% 24.65%
EBIT Margin		 32.07% 34.52% 30.94% 19.36% 29.87% 12.40% 27.36% 26.74% 14.61% 10.43% 15.08%
Profit (Net Income) Margin		 22.50% 23.22% 18.82% 17.36% 23.69% 10.09% 20.55% 20.40% 8.97% 7.61% 6.92%
Tax Burden Percent		 77.41% 75.51% 68.71% 109.43% 93.54% 136.02% 88.91% 87.89% 77.97% 115.34% 64.17%
Interest Burden Percent		 90.64% 89.09% 88.50% 81.96% 84.81% 59.85% 84.49% 86.83% 78.77% 63.24% 71.52%
Effective Tax Rate		 22.59% 24.49% 31.29% -9.43% 6.46% -36.02% 11.09% 12.11% 22.03% -15.34% 35.83%
Return on Invested Capital (ROIC)		 27.33% 19.49% 14.94% 16.82% 43.83% 28.38% 18.49% 20.80% 15.57% 17.37% 15.68%
ROIC Less NNEP Spread (ROIC-NNEP)		 23.60% 16.04% 11.74% 13.81% 32.00% 7.54% 12.39% 14.03% 5.43% 5.75% 6.85%
Return on Net Nonoperating Assets (RNNOA)		 153.57% 119.26% 94.16% -356.44% -138.70% 159.31% 62.46% 51.59% 19.63% 44.92% 6,209.32%
Return on Equity (ROE)		 180.90% 138.75% 109.09% -339.62% -94.86% 187.70% 80.95% 72.40% 35.20% 62.29% 6,225.00%
Cash Return on Invested Capital (CROIC)		 -60.86% -10.53% 4.53% 39.25% 110.01% -103.54% 28.20% 35.07% 38.16% 4.16% 25.29%
Operating Return on Assets (OROA)		 18.20% 14.85% 12.76% 9.75% 13.38% 4.74% 10.35% 10.88% 5.80% 4.35% 6.85%
Return on Assets (ROA)		 12.77% 9.99% 7.76% 8.74% 10.62% 3.86% 7.77% 8.30% 3.56% 3.18% 3.15%
Return on Common Equity (ROCE)		 180.90% 138.75% 109.09% -339.62% -94.86% 186.90% 80.81% 72.26% 35.12% 61.95% 2,517.46%
Return on Equity Simple (ROE_SIMPLE)		 130.39% 128.41% 104.16% -67.33% -96.45% 35.35% 74.95% 68.65% 47.04% 128.90% 0.00%
Net Operating Profit after Tax (NOPAT)		 5,835 7,052 6,558 6,985 12,145 15,456 15,937 15,923 9,946 10,539 9,673
NOPAT Margin		 25.52% 27.51% 23.24% 21.33% 36.51% 33.74% 28.36% 27.43% 18.31% 18.71% 15.82%
Net Nonoperating Expense Percent (NNEP)		 3.73% 3.45% 3.20% 3.00% 11.84% 20.84% 6.10% 6.78% 10.14% 11.62% 8.83%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 19.77% 14.25% 14.95% 15.05%
Cost of Revenue to Revenue		 19.69% 22.75% 24.96% 23.56% 22.36% 36.60% 31.04% 31.20% 39.02% 30.01% 37.97%
SG&A Expenses to Revenue		 27.94% 22.94% 22.31% 22.59% 20.87% 24.67% 23.97% 26.29% 23.70% 31.08% 22.91%
R&D to Revenue		 19.40% 17.88% 18.90% 32.83% 20.42% 13.93% 12.32% 11.21% 14.13% 22.71% 14.87%
Operating Expenses to Revenue		 47.34% 40.82% 41.21% 56.95% 38.61% 38.59% 37.06% 37.60% 37.50% 53.77% 37.39%
Earnings before Interest and Taxes (EBIT)		 7,331 8,849 8,731 6,341 9,935 5,678 15,373 15,521 7,934 5,876 9,224
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 8,167 10,038 10,232 8,106 11,952 12,149 23,894 23,988 16,632 14,262 17,363
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 16.90 15.69 22.45 0.00 0.00 12.42 13.98 15.22 25.24 93.56 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.92 2.84 4.05 3.26 3.20 3.55 3.83 4.52 4.81 5.52 6.55
Price to Earnings (P/E)		 12.96 12.22 21.55 18.77 13.51 35.18 18.66 22.18 53.77 72.72 94.80
Dividend Yield		 4.95% 5.09% 3.57% 5.06% 5.94% 5.13% 4.27% 3.80% 4.00% 3.52% 2.89%
Earnings Yield		 7.72% 8.18% 4.64% 5.33% 7.40% 2.84% 5.36% 4.51% 1.86% 1.38% 1.05%
Enterprise Value to Invested Capital (EV/IC)		 3.04 2.64 3.37 4.12 7.19 2.65 3.44 4.45 5.43 5.76 7.88
Enterprise Value to Revenue (EV/Rev)		 4.09 4.28 5.51 4.64 4.00 5.23 5.02 5.45 5.67 6.61 7.56
Enterprise Value to EBITDA (EV/EBITDA)		 11.45 10.93 15.20 18.76 11.15 19.73 11.80 13.19 18.51 26.11 26.64
Enterprise Value to EBIT (EV/EBIT)		 12.75 12.40 17.81 23.98 13.41 42.22 18.34 20.38 38.79 63.38 50.15
Enterprise Value to NOPAT (EV/NOPAT)		 16.02 15.56 23.71 21.77 10.97 15.51 17.69 19.87 30.95 35.34 47.83
Enterprise Value to Operating Cash Flow (EV/OCF)		 12.41 15.59 15.61 11.33 10.00 13.63 12.38 12.68 13.48 19.80 24.31
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 78.10 9.33 4.37 0.00 11.60 11.78 12.63 147.41 29.65
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 8.96 9.75 10.39 -6.49 -8.17 6.57 4.97 3.66 5.71 19.96 -20.91
Long-Term Debt to Equity		 8.35 9.66 9.13 -5.86 -7.71 5.92 4.16 3.42 5.02 17.94 -18.26
Financial Leverage		 6.51 7.44 8.02 -25.80 -4.33 21.12 5.04 3.68 3.61 7.82 906.48
Leverage Ratio		 14.17 13.89 14.06 -38.86 -8.93 48.67 10.41 8.72 9.88 19.61 1,978.83
Compound Leverage Factor		 12.84 12.37 12.45 -31.85 -7.58 29.12 8.80 7.57 7.78 12.40 1,415.26
Debt to Total Capital		 89.96% 90.70% 91.22% 118.22% 113.96% 86.79% 83.24% 78.54% 85.10% 95.23% 105.02%
Short-Term Debt to Total Capital		 6.18% 0.81% 11.05% 11.45% 6.41% 8.57% 13.56% 5.13% 10.30% 9.65% 13.31%
Long-Term Debt to Total Capital		 83.78% 89.89% 80.18% 106.77% 107.55% 78.22% 69.68% 73.41% 74.80% 85.58% 91.71%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.03% 0.04% 0.05% 0.06% 0.07%
Common Equity to Total Capital		 10.04% 9.30% 8.78% -18.22% -13.96% 13.19% 16.73% 21.42% 14.85% 4.72% -5.09%
Debt to EBITDA		 4.33 4.50 5.18 6.76 5.58 7.08 3.21 2.64 3.57 4.71 3.89
Net Debt to EBITDA		 3.28 3.68 4.02 5.59 2.23 6.36 2.79 2.24 2.78 4.30 3.57
Long-Term Debt to EBITDA		 4.03 4.46 4.55 6.11 5.27 6.38 2.69 2.47 3.14 4.23 3.39
Debt to NOPAT		 6.06 6.41 8.08 7.85 5.49 5.57 4.81 3.97 5.97 6.37 6.98
Net Debt to NOPAT		 4.60 5.24 6.27 6.49 2.20 5.00 4.18 3.38 4.65 5.82 6.41
Long-Term Debt to NOPAT		 5.64 6.35 7.10 7.09 5.19 5.02 4.03 3.71 5.25 5.73 6.09
Altman Z-Score		 1.88 1.75 2.04 1.92 1.93 1.11 1.69 2.12 1.81 1.78 2.15
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.43% 0.17% 0.19% 0.25% 0.55% 59.56%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.50 1.65 1.28 0.98 3.18 0.84 0.79 0.96 0.87 0.66 0.67
Quick Ratio		 1.21 1.14 0.89 0.78 2.91 0.60 0.56 0.69 0.63 0.43 0.41
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12,990 -3,813 1,991 16,303 30,479 -56,386 24,305 26,848 24,372 2,527 15,604
Operating Cash Flow to CapEx		 1,416.35% 1,469.94% 1,882.80% 2,104.55% 2,413.77% 2,204.01% 2,894.16% 3,588.92% 2,939.38% 1,930.80% 1,567.55%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.57 0.43 0.41 0.50 0.45 0.38 0.38 0.41 0.40 0.42 0.45
Accounts Receivable Turnover		 5.40 5.40 5.73 6.26 6.15 6.43 5.98 5.47 4.85 5.10 5.20
Inventory Turnover		 3.17 3.69 4.62 4.81 4.35 6.54 5.42 5.40 5.52 4.08 5.09
Fixed Asset Turnover		 9.05 9.92 10.44 11.52 11.38 11.16 10.85 11.56 10.95 11.13 11.37
Accounts Payable Turnover		 0.58 0.65 0.72 0.70 0.63 1.05 0.81 0.75 0.76 0.54 0.70
Days Sales Outstanding (DSO)		 67.58 67.54 63.68 58.35 59.32 56.78 61.05 66.74 75.29 71.51 70.15
Days Inventory Outstanding (DIO)		 115.30 98.98 79.02 75.90 83.85 55.77 67.35 67.58 66.12 89.39 71.77
Days Payable Outstanding (DPO)		 625.25 558.33 508.08 523.92 582.97 348.29 448.33 484.70 482.68 675.79 524.07
Cash Conversion Cycle (CCC)		 -442.36 -391.81 -365.38 -389.67 -439.81 -235.74 -319.93 -350.37 -341.27 -514.89 -382.15
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 30,759 41,624 46,191 36,873 18,539 90,381 82,013 71,088 56,662 64,674 58,743
Invested Capital Turnover		 1.07 0.71 0.64 0.79 1.20 0.84 0.65 0.76 0.85 0.93 0.99
Increase / (Decrease) in Invested Capital		 18,825 10,865 4,567 -9,318 -18,334 71,842 -8,368 -10,925 -14,426 8,012 -5,931
Enterprise Value (EV)		 93,473 109,742 155,500 152,086 133,216 239,699 281,950 316,377 307,792 372,436 462,620
Market Capitalization		 66,659 72,754 114,406 106,767 106,505 162,394 215,345 262,543 261,490 311,087 400,607
Book Value per Share		 $2.41 $2.85 $3.19 ($5.61) ($5.53) $7.41 $8.72 $9.76 $5.87 $1.88 ($1.85)
Tangible Book Value per Share		 ($17.70) ($24.42) ($23.96) ($30.14) ($28.69) ($58.30) ($52.56) ($46.56) ($43.92) ($51.89) ($51.80)
Total Capital		 39,311 49,830 58,070 46,354 58,556 99,153 92,120 80,558 69,782 70,508 64,268
Total Debt		 35,366 45,194 52,973 54,800 66,728 86,056 76,684 63,271 59,385 67,144 67,496
Total Long-Term Debt		 32,935 44,792 46,558 49,492 62,975 77,554 64,189 59,135 52,194 60,340 58,941
Net Debt		 26,814 36,988 41,094 45,319 26,711 77,284 66,577 53,801 46,265 61,310 61,971
Capital Expenditures (CapEx)		 532 479 529 638 552 798 787 695 777 974 1,214
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -556 385 1,208 -3,047 -2,237 -4,465 -4,601 -6,168 -10,464 -11,918 -10,929
Debt-free Net Working Capital (DFNWC)		 7,851 6,808 10,997 5,014 37,687 4,014 5,229 3,061 2,352 -6,363 -5,672
Net Working Capital (NWC)		 5,420 6,406 4,582 -294 33,934 -4,488 -7,266 -1,075 -4,839 -13,167 -14,227
Net Nonoperating Expense (NNE)		 691 1,099 1,249 1,298 4,263 10,834 4,388 4,078 5,073 6,253 5,440
Net Nonoperating Obligations (NNO)		 26,814 36,988 41,094 45,319 26,711 77,284 66,577 53,801 46,265 61,310 61,971
Total Depreciation and Amortization (D&A)		 836 1,189 1,501 1,765 2,017 6,471 8,521 8,467 8,698 8,386 8,139
Debt-free, Cash-free Net Working Capital to Revenue		 -2.43% 1.50% 4.28% -9.30% -6.72% -9.75% -8.19% -10.62% -19.26% -21.16% -17.87%
Debt-free Net Working Capital to Revenue		 34.35% 26.55% 38.97% 15.31% 113.29% 8.76% 9.30% 5.27% 4.33% -11.30% -9.27%
Net Working Capital to Revenue		 23.71% 24.99% 16.24% -0.90% 102.01% -9.80% -12.93% -1.85% -8.91% -23.37% -23.26%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.15 $3.65 $3.31 $3.67 $5.30 $2.73 $6.48 $6.65 $2.73 $2.40 $2.37
Adjusted Weighted Average Basic Shares Outstanding		 1.63B 1.62B 1.60B 1.54B 1.48B 1.67B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Diluted Earnings per Share		 $3.13 $3.63 $3.30 $3.66 $5.28 $2.72 $6.45 $6.63 $2.72 $2.39 $2.36
Adjusted Weighted Average Diluted Shares Outstanding		 1.64B 1.63B 1.60B 1.55B 1.48B 1.67B 1.78B 1.78B 1.77B 1.77B 1.77B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.61B 1.59B 1.59B 1.48B 1.48B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Normalized Net Operating Profit after Tax (NOPAT)		 5,835 7,052 6,558 4,468 12,145 7,954 15,937 15,923 9,946 6,396 9,673
Normalized NOPAT Margin		 25.52% 27.51% 23.24% 13.64% 36.51% 17.37% 28.36% 27.43% 18.31% 11.35% 15.82%
Pre Tax Income Margin		 29.07% 30.75% 27.39% 15.87% 25.33% 7.42% 23.11% 23.21% 11.51% 6.60% 10.79%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 64.04% 62.44% 77.36% 98.12% 80.77% 166.94% 80.19% 84.79% 216.27% 257.23% 275.38%
Augmented Payout Ratio		 215.05% 164.94% 103.92% 310.08% 94.13% 188.53% 88.28% 97.34% 257.52% 299.39% 299.08%

Quarterly Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 1,767,384,632.00 1,768,169,012.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 1,767,384,632.00 1,768,169,012.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 1.03 0.39
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -5.97% -5.42% 0.70% 4.31% 3.83% 5.60% 8.39% 6.65% 9.10% 10.04% 12.43%
EBITDA Growth		 -35.43% -34.51% 40.12% -10.16% 3.66% -87.92% 1.05% -10.47% -27.56% 1,098.65% -16.34%
EBIT Growth		 -51.99% -53.79% 137.67% -13.45% 13.78% -204.34% 3.62% -15.84% -48.37% 300.30% -26.40%
NOPAT Growth		 -49.69% -52.65% 55.75% -27.02% 38.22% -148.02% 32.44% 15.86% -82.56% 396.38% -7.60%
Net Income Growth		 -54.93% -66.67% 469.29% -32.26% -12.18% -102.79% -6.05% -31.46% -87.98% 7,991.30% -45.93%
EPS Growth		 -54.75% -67.86% 492.31% -32.46% -12.00% -106.67% -6.49% -32.47% -88.64% 3,500.00% -45.83%
Operating Cash Flow Growth		 -0.37% -36.01% -3.65% -64.06% -28.08% 48.29% -59.53% 126.90% 28.95% -25.96% 134.19%
Free Cash Flow Firm Growth		 31.45% 7.00% -53.62% -78.89% -145.51% -154.55% -90.15% 0.96% 233.78% 199.64% 1,653.80%
Invested Capital Growth		 -19.33% -20.29% -6.93% -1.28% 17.35% 14.14% 3.48% -0.72% -13.53% -9.17% -14.12%
Revenue Q/Q Growth		 0.45% 2.69% -13.92% 17.48% -0.01% 4.44% -11.65% 15.59% 2.29% 5.34% -9.72%
EBITDA Q/Q Growth		 -13.86% -20.06% 16.80% 11.70% -0.61% -90.68% 876.75% -1.04% -19.57% 54.18% -31.83%
EBIT Q/Q Growth		 -23.27% -32.37% 38.87% 20.11% 0.87% -162.02% 237.91% -2.45% -38.13% 140.62% -49.32%
NOPAT Q/Q Growth		 -40.65% 4.43% 0.70% 16.94% 12.40% -136.28% 377.75% 2.30% -83.08% 516.60% -13.41%
Net Income Q/Q Growth		 -12.14% -53.73% 66.50% 0.07% 13.91% -101.47% 5,704.35% -27.00% -80.02% 865.43% -61.60%
EPS Q/Q Growth		 -12.28% -55.00% 71.11% 0.00% 14.29% -103.41% 2,500.00% -27.78% -80.77% 920.00% -61.76%
Operating Cash Flow Q/Q Growth		 19.86% -37.25% -15.00% -43.79% 139.85% 29.39% -76.80% 215.17% 36.31% -25.71% -26.62%
Free Cash Flow Firm Q/Q Growth		 1.42% 1.90% -58.25% -51.07% -318.61% -22.15% 107.54% 401.28% 189.69% -9.03% 32.76%
Invested Capital Q/Q Growth		 -8.56% -4.46% 12.38% 0.55% 8.70% -7.07% 1.88% -3.52% -5.32% -2.39% -3.67%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 52.96% 56.18% 65.41% 64.47% 70.87% 78.18% 68.15% 71.82% 49.39% 60.04% 66.92%
EBITDA Margin		 32.93% 25.63% 34.78% 33.07% 32.88% 2.93% 32.43% 27.76% 21.83% 31.95% 24.13%
Operating Margin		 16.38% 22.34% 22.73% 27.64% 26.49% -9.87% 27.98% 31.73% 12.07% 27.34% 26.60%
EBIT Margin		 16.88% 11.12% 17.94% 18.34% 18.50% -10.99% 17.15% 14.47% 8.75% 20.00% 11.23%
Profit (Net Income) Margin		 12.79% 5.76% 11.15% 9.49% 10.82% -0.15% 9.66% 6.10% 1.19% 10.92% 4.65%
Tax Burden Percent		 91.19% 67.99% 78.18% 63.98% 75.05% 1.01% 77.60% 60.55% 26.33% 68.03% 67.08%
Interest Burden Percent		 83.07% 76.23% 79.48% 80.92% 77.91% 136.77% 72.60% 69.62% 51.70% 80.29% 61.70%
Effective Tax Rate		 8.81% 32.01% 21.82% 36.02% 24.95% 0.00% 22.40% 39.45% 73.67% 31.97% 32.92%
Return on Invested Capital (ROIC)		 12.40% 12.92% 14.64% 15.10% 17.13% -6.41% 19.23% 17.57% 2.92% 18.44% 18.30%
ROIC Less NNEP Spread (ROIC-NNEP)		 11.83% 10.22% 13.16% 12.92% 14.76% -4.52% 16.55% 14.22% 2.42% 16.37% 15.20%
Return on Net Nonoperating Assets (RNNOA)		 43.97% 36.95% 68.28% 71.55% 89.80% -35.31% 208.92% 257.31% 88.21% 14,835.28% -376.69%
Return on Equity (ROE)		 56.37% 49.86% 82.92% 86.65% 106.93% -41.72% 228.15% 274.88% 91.13% 14,853.71% -358.39%
Cash Return on Invested Capital (CROIC)		 39.88% 38.16% 22.62% 15.71% -0.67% 4.16% 14.62% 22.12% 34.61% 25.29% 30.45%
Operating Return on Assets (OROA)		 6.71% 4.42% 6.89% 7.27% 7.35% -4.59% 6.90% 6.05% 3.77% 9.09% 5.17%
Return on Assets (ROA)		 5.08% 2.29% 4.28% 3.77% 4.30% -0.06% 3.89% 2.55% 0.51% 4.96% 2.14%
Return on Common Equity (ROCE)		 56.24% 49.74% 82.65% 86.32% 106.49% -41.49% 226.18% 271.26% 88.98% 6,007.02% -364.37%
Return on Equity Simple (ROE_SIMPLE)		 53.92% 0.00% 74.98% 78.93% 85.10% 0.00% 295.99% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 2,080 2,172 2,187 2,558 2,875 -1,043 2,897 2,963 501 3,091 2,677
NOPAT Margin		 14.94% 15.19% 17.77% 17.69% 19.88% -6.91% 21.71% 19.21% 3.18% 18.60% 17.84%
Net Nonoperating Expense Percent (NNEP)		 0.57% 2.69% 1.47% 2.17% 2.37% -1.90% 2.68% 3.35% 0.50% 2.07% 3.10%
Return On Investment Capital (ROIC_SIMPLE)		 - 3.11% - - - -1.48% 4.06% 4.21% 0.76% 4.81% 4.04%
Cost of Revenue to Revenue		 47.04% 43.82% 34.59% 35.53% 29.13% 21.82% 31.85% 28.18% 50.61% 39.96% 33.08%
SG&A Expenses to Revenue		 24.21% 20.37% 26.93% 23.35% 29.65% 43.24% 24.68% 26.43% 22.62% 18.49% 23.85%
R&D to Revenue		 12.37% 13.47% 15.75% 13.47% 14.73% 44.86% 15.49% 13.82% 14.70% 15.52% 16.48%
Operating Expenses to Revenue		 36.58% 33.84% 42.68% 36.82% 44.38% 88.05% 40.17% 40.09% 37.32% 32.70% 40.33%
Earnings before Interest and Taxes (EBIT)		 2,351 1,590 2,208 2,652 2,675 -1,659 2,288 2,232 1,381 3,323 1,684
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4,586 3,666 4,282 4,783 4,754 443 4,327 4,282 3,444 5,310 3,620
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 20.78 25.24 39.42 44.28 57.37 93.56 258.09 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 4.56 4.81 5.80 5.46 6.23 5.52 6.39 5.57 6.81 6.55 6.07
Price to Earnings (P/E)		 38.58 53.77 52.67 56.21 67.56 72.72 87.36 86.39 170.06 94.80 104.92
Dividend Yield		 4.11% 4.00% 3.35% 3.57% 3.13% 3.52% 3.03% 3.47% 2.81% 2.89% 3.08%
Earnings Yield		 2.59% 1.86% 1.90% 1.78% 1.48% 1.38% 1.14% 1.16% 0.59% 1.05% 0.95%
Enterprise Value to Invested Capital (EV/IC)		 5.03 5.43 5.83 5.58 5.89 5.76 6.54 6.12 7.79 7.88 7.86
Enterprise Value to Revenue (EV/Rev)		 5.41 5.67 6.82 6.50 7.38 6.61 7.51 6.67 7.86 7.56 7.08
Enterprise Value to EBITDA (EV/EBITDA)		 16.08 18.51 20.79 20.64 23.43 26.11 30.12 28.16 37.53 26.64 26.70
Enterprise Value to EBIT (EV/EBIT)		 30.51 38.79 40.30 40.61 44.89 63.38 72.36 70.24 110.54 50.15 51.58
Enterprise Value to NOPAT (EV/NOPAT)		 24.32 30.95 36.42 38.46 41.55 35.34 36.87 28.48 35.95 47.83 47.59
Enterprise Value to Operating Cash Flow (EV/OCF)		 11.70 13.48 16.37 19.17 24.81 19.80 26.28 20.16 22.48 24.31 20.95
Enterprise Value to Free Cash Flow (EV/FCFF)		 11.27 12.63 24.85 35.30 0.00 147.41 45.49 27.56 20.88 29.65 23.85
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 5.01 5.71 9.20 10.36 11.71 19.96 47.80 -510.73 -26.45 -20.91 -11.02
Long-Term Debt to Equity		 4.59 5.02 7.93 8.51 9.64 17.94 44.14 -456.22 -24.23 -18.26 -9.76
Financial Leverage		 3.72 3.61 5.19 5.54 6.08 7.82 12.63 18.09 36.38 906.48 -24.78
Leverage Ratio		 9.86 9.88 13.27 14.06 15.37 19.61 29.98 41.77 79.87 1,978.83 -52.94
Compound Leverage Factor		 8.19 7.53 10.55 11.38 11.97 26.82 21.76 29.08 41.30 1,588.78 -32.66
Debt to Total Capital		 83.36% 85.10% 90.19% 91.19% 92.13% 95.23% 97.95% 100.20% 103.93% 105.02% 109.98%
Short-Term Debt to Total Capital		 7.02% 10.30% 12.43% 16.25% 16.29% 9.65% 7.52% 10.69% 8.73% 13.31% 12.57%
Long-Term Debt to Total Capital		 76.34% 74.80% 77.77% 74.94% 75.84% 85.58% 90.44% 89.50% 95.20% 91.71% 97.41%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.05% 0.05% 0.05% 0.06% 0.05% 0.06% 0.06% 0.06% 0.07% 0.07% 0.07%
Common Equity to Total Capital		 16.60% 14.85% 9.76% 8.75% 7.82% 4.72% 1.99% -0.26% -3.99% -5.09% -10.05%
Debt to EBITDA		 3.27 3.57 4.14 4.08 4.07 4.71 4.89 5.11 5.50 3.89 4.37
Net Debt to EBITDA		 2.54 2.78 3.12 3.30 3.63 4.30 4.50 4.61 5.02 3.57 3.79
Long-Term Debt to EBITDA		 3.00 3.14 3.57 3.35 3.35 4.23 4.51 4.56 5.04 3.39 3.87
Debt to NOPAT		 4.95 5.97 7.26 7.60 7.21 6.37 5.98 5.16 5.27 6.98 7.80
Net Debt to NOPAT		 3.84 4.65 5.46 6.16 6.44 5.82 5.51 4.67 4.81 6.41 6.76
Long-Term Debt to NOPAT		 4.53 5.25 6.26 6.25 5.94 5.73 5.52 4.61 4.83 6.09 6.91
Altman Z-Score		 1.67 1.65 1.72 1.68 1.78 1.59 1.93 1.69 2.02 2.00 1.84
Noncontrolling Interest Sharing Ratio		 0.24% 0.25% 0.32% 0.38% 0.41% 0.55% 0.86% 1.32% 2.36% 59.56% -1.67%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.96 0.87 0.94 0.81 0.65 0.66 0.76 0.74 0.72 0.67 0.80
Quick Ratio		 0.71 0.63 0.72 0.59 0.44 0.43 0.48 0.48 0.47 0.41 0.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 16,289 16,598 6,930 3,391 -7,413 -9,055 683 3,423 9,917 9,022 11,978
Operating Cash Flow to CapEx		 3,458.45% 2,318.54% 2,093.26% 942.32% 2,187.55% 2,421.99% 695.74% 1,915.61% 1,843.57% 1,586.02% 1,444.91%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.40 0.40 0.38 0.40 0.40 0.42 0.40 0.42 0.43 0.45 0.46
Accounts Receivable Turnover		 4.98 4.85 4.65 4.74 4.85 5.10 4.70 4.79 4.92 5.20 5.03
Inventory Turnover		 5.41 5.52 5.28 5.37 4.71 4.08 3.85 3.71 4.42 5.09 5.05
Fixed Asset Turnover		 11.22 10.95 10.98 11.04 11.02 11.13 11.23 11.32 11.23 11.37 11.50
Accounts Payable Turnover		 0.73 0.76 0.76 0.79 0.66 0.54 0.54 0.55 0.65 0.70 0.75
Days Sales Outstanding (DSO)		 73.33 75.29 78.57 77.03 75.20 71.51 77.71 76.22 74.17 70.15 72.50
Days Inventory Outstanding (DIO)		 67.50 66.12 69.16 67.97 77.42 89.39 94.74 98.30 82.65 71.77 72.27
Days Payable Outstanding (DPO)		 501.67 482.68 480.46 463.07 552.32 675.79 673.65 659.46 564.41 524.07 489.20
Cash Conversion Cycle (CCC)		 -360.84 -341.27 -332.72 -318.07 -399.70 -514.89 -501.20 -484.94 -407.59 -382.15 -344.43
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 59,310 56,662 63,674 64,026 69,598 64,674 65,888 63,566 60,182 58,743 56,587
Invested Capital Turnover		 0.83 0.85 0.82 0.85 0.86 0.93 0.89 0.91 0.92 0.99 1.03
Increase / (Decrease) in Invested Capital		 -14,209 -14,426 -4,743 -833 10,288 8,012 2,214 -460 -9,416 -5,931 -9,301
Enterprise Value (EV)		 298,520 307,792 371,297 357,373 409,620 372,436 430,958 388,821 468,925 462,620 444,638
Market Capitalization		 251,304 261,490 315,630 300,125 346,054 311,087 366,490 325,072 406,101 400,607 381,395
Book Value per Share		 $6.85 $5.87 $4.53 $3.84 $3.42 $1.88 $0.80 ($0.10) ($1.50) ($1.85) ($3.76)
Tangible Book Value per Share		 ($44.53) ($43.92) ($49.54) ($49.18) ($54.30) ($51.89) ($52.31) ($52.57) ($52.41) ($51.80) ($52.65)
Total Capital		 72,875 69,782 82,048 77,455 77,150 70,508 71,351 70,343 66,144 64,268 66,246
Total Debt		 60,746 59,385 74,001 70,634 71,079 67,144 69,889 70,481 68,743 67,496 72,858
Total Long-Term Debt		 55,631 52,194 63,805 58,048 58,509 60,340 64,527 62,959 62,971 58,941 64,532
Net Debt		 47,181 46,265 55,627 57,205 63,527 61,310 64,426 63,704 62,781 61,971 63,199
Capital Expenditures (CapEx)		 219 205 193 241 249 291 235 269 381 329 265
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9,724 -10,464 -10,524 -8,670 -9,992 -11,918 -8,542 -9,451 -10,751 -10,929 -9,636
Debt-free Net Working Capital (DFNWC)		 3,566 2,352 7,545 4,487 -2,707 -6,363 -3,366 -2,984 -5,080 -5,672 -245
Net Working Capital (NWC)		 -1,549 -4,839 -2,651 -8,099 -15,277 -13,167 -8,728 -10,506 -10,852 -14,227 -8,571
Net Nonoperating Expense (NNE)		 299 1,348 815 1,185 1,311 -1,020 1,608 2,022 313 1,276 1,980
Net Nonoperating Obligations (NNO)		 47,181 46,265 55,627 57,205 63,527 61,310 64,426 63,704 62,781 61,971 63,199
Total Depreciation and Amortization (D&A)		 2,235 2,076 2,074 2,131 2,079 2,102 2,039 2,050 2,063 1,987 1,936
Debt-free, Cash-free Net Working Capital to Revenue		 -17.64% -19.26% -19.34% -15.76% -17.99% -21.16% -14.89% -16.20% -18.03% -17.87% -15.34%
Debt-free Net Working Capital to Revenue		 6.47% 4.33% 13.87% 8.16% -4.87% -11.30% -5.87% -5.12% -8.52% -9.27% -0.39%
Net Working Capital to Revenue		 -2.81% -8.91% -4.87% -14.73% -27.51% -23.37% -15.21% -18.01% -18.19% -23.26% -13.64%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.00 $0.46 $0.77 $0.77 $0.88 ($0.02) $0.72 $0.52 $0.10 $1.03 $0.39
Adjusted Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Diluted Earnings per Share		 $1.00 $0.45 $0.77 $0.77 $0.88 ($0.03) $0.72 $0.52 $0.10 $1.02 $0.39
Adjusted Weighted Average Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Normalized Net Operating Profit after Tax (NOPAT)		 2,080 2,172 2,187 2,558 2,875 -1,043 2,897 2,963 1,333 3,091 2,677
Normalized NOPAT Margin		 14.94% 15.19% 17.77% 17.69% 19.88% -6.91% 21.71% 19.21% 8.45% 18.60% 17.84%
Pre Tax Income Margin		 14.02% 8.47% 14.26% 14.84% 14.41% -15.02% 12.45% 10.08% 4.53% 16.05% 6.93%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 159.78% 216.27% 177.38% 201.40% 212.33% 257.23% 265.95% 300.66% 480.08% 275.38% 324.58%
Augmented Payout Ratio		 190.03% 257.52% 200.35% 227.16% 239.43% 299.39% 300.31% 339.03% 539.96% 299.08% 366.63%

Financials Breakdown Chart

Key Financial Trends

AbbVie Inc. (NYSE: ABBV) has shown a mix of revenue growth, solid cash generation, and a sizable debt load over the last four years. In 2025 the company continued to post positive net income and strong operating cash flow, but gross margins have fluctuated, and leverage remains a key consideration for investors.

  • Revenue has trended higher into 2025, with Q4 2025 operating revenue of $16.618 billion, up from $15.102 billion in Q4 2024.
  • Net income attributable to common shareholders has remained positive in the latest four quarters, around $0.9–$1.9 billion per quarter (example: Q2 2025 roughly $0.938B; Q3 2025 about $1.860B; Q4 2025 about $1.816B; Q1 2025 about $1.286B).
  • Operating cash flow has been robust in 2025, with quarterly net cash from continuing operating activities often in the $5–7 billion range (peak around $7.0B in Q3 2025).
  • Dividend per share rose to $1.64 in 2025, reflecting continued income support for shareholders (consistent 2024 levels at $1.55, rising in 2025).
  • Research & development (R&D) expense remains substantial, signaling ongoing investment in the company’s pipeline and potential long-term growth.
  • Long-term debt remains elevated, typically in the $60–65 billion range across 2024–2025, highlighting ongoing leverage to fund operations and returns to shareholders.
  • Capital expenditures and other investing activities run in the low hundreds of millions per quarter, indicating continued investment in PP&E and portfolio activities, though annual investing outflows vary with acquisitions or asset sales.
  • Gross margin compressed in Q4 2025 relative to Q4 2024 (roughly 60% in Q4 2025 vs about 78% in Q4 2024), signaling margin pressure despite higher revenue.
  • Net income margin and overall profitability have shown fluctuation in 2025, with quarterly earnings delivering less relative margin than peak years, partially due to higher operating costs and ongoing investments.
  • Net financing outflows remained meaningful, reflecting dividends, debt activity, and other financing movements that can pressure near-term liquidity and require ongoing capitalization decisions.
05/26/26 04:29 PM ETAI Generated. May Contain Errors.

AbbVie Financials - Frequently Asked Questions

According to the most recent income statement we have on file, AbbVie's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

AbbVie's net income were at $4.23 billion at the end of 2025, a 1.2% decrease from 2024, and a 17.7% decrease since 2015. View AbbVie's forecast to see where analysts expect AbbVie to go next.

AbbVie's total operating income in 2025 was $15.08 billion, based on the following breakdown:
  • Total Gross Profit: $37.94 billion
  • Total Operating Expenses: $22.87 billion

Over the last 10 years, AbbVie's total revenue changed from $22.86 billion in 2015 to $61.16 billion in 2025, a change of 167.6%.

AbbVie's total liabilities were at $137.19 billion at the end of 2025, a 4.1% increase from 2024, and a 179.4% increase since 2015.

In the past 10 years, AbbVie's cash and equivalents has ranged from $5.10 billion in 2016 to $39.92 billion in 2019, and is currently $5.23 billion as of their latest financial filing in 2025.

Over the last 10 years, AbbVie's book value per share changed from 2.41 in 2015 to -1.85 in 2025, a change of -176.7%.


Related Companies

Financial statements for NYSE:ABBV last updated on 5/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The digital asset institutions are buying before headlines hit
JPMorgan is processing $2 billion a day through new digital rails. BlackRock's tokenized fund crossed $2.8 bil...
Awesomely, LLC | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The Fed is trapped (and your savings will pay the price)
In 1910, six men representing one quarter of the world's wealth gathered in secret on Jekyll Island. The Morga...
Decentralized Masters | Sponsoredtc pixel
You cannot escape this reality
The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Your $29.97 book is free today
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel